New cream trio aims to outshine standard melasma treatment
NCT ID NCT07676994
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study compares a new combination cream (containing isobutylamido-thiazolyl-resorcinol, retinoic acid, and dexamethasone) to the standard Kligman's formula for treating melasma, a common skin condition causing dark patches. The trial enrolls 56 women aged 16–60 who apply the cream nightly for three months. Researchers measure changes in melasma severity and quality of life at 4, 8, and 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
New trio combination (0.1% isobutylamido-thiazolyl-resorcinol, 0.1% retinoic acid, 0.1% dexamethasone)
What this could lead to
If effective, this cream could offer a new option for treating melasma with potentially fewer side effects than standard therapy.
What could go wrong
This is a small, early-phase trial with only 56 participants, so results may not apply to everyone. Possible side effects include redness and burning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELASMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ghurki Trust Teaching Hospital
Lahore, Pakistan